Vaxinia MAST Trial:
47 heavily pre-treated patients have been dosed to date (24 April 2024), of which 40 patients are evaluable meaning they received at least their first scan at day 42
• Nearly half of the evaluable patients (48%) have remained on treatment for more than 3 months, representing significant disease control; 3 monotherapy patients have remained on treatment for over 200 days
perhaps a new update soon ?
onCARlytics OASIS Trial:
Preliminary early combination data are expected in the fourth quarter of 2024.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-16
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
